Description

DAPAZIGA – 10 TAB is a once-daily oral antidiabetic tablet containing Dapagliflozin 10 mg, a selective SGLT2 (sodium-glucose co-transporter-2) inhibitor. It is primarily prescribed for adults with type 2 diabetes mellitus to improve glycemic control, and is also recommended for patients with heart failure or chronic kidney disease (CKD) due to its cardiovascular and renal benefits.

Mechanism of Action:

Dapagliflozin lowers blood sugar by blocking glucose reabsorption in the kidneys and promoting its excretion through urine. It works independently of insulin, making it effective across a range of diabetes progression stages.

Therapeutic Uses:

• Type 2 Diabetes Mellitus (T2DM) – improves blood sugar control

• Heart Failure with Reduced Ejection Fraction (HFrEF) – reduces hospitalization risk

• Chronic Kidney Disease (CKD) – slows progression and reduces risk of renal failure

• Can be used alone or with other antidiabetic drugs like metformin or insulin

Key Benefits:

• Lowers HbA1c, fasting, and postprandial blood glucose

• Promotes weight loss and reduces blood pressure

• Provides cardiorenal protection in at-risk patients

• Low risk of hypoglycemia when used as monotherapy

Manufactured under WHO-GMP and ISO-certified facilities, DAPAZIGA – 10 TAB is exported by BLUEPILL EXPRESS, a globally trusted pharmaceutical supplier. BLUEPILL EXPRESS ensures compliance, quality assurance, and timely international delivery to markets across Asia, Africa, the Middle East, Latin America, and Europe.